FDA approves Regeneron's Pasatru as second therapy for rare bone disease FOP

The US FDA approved Regeneron's Pasatru as the second therapy for fibrodysplasia ossificans progressiva (FOP), reducing new bone lesion formation and flare-ups in adults. This approval follows positive Phase III trial results and distinguishes Pasatru from the first approved treatment Sohonos by targeting Activin A.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 19 Aug 2026 and 20 Aug 2026.